Piperidine, 1-heptyl-4-methyl

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Piperidine, 1-heptyl-4-methyl
• 英文别名: 1-heptyl-4-methylpiperidine
• 化学式: C₁₃H₂₇N
• 分子量: 197.364
• InChiKey: CZJBHSBFUBBFQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-甲基哌啶 、 庚醛 在 imine reductase from Streptomyces ipomoeae 、 还原型辅酶II(NADPH)四钠盐 作用下， 以 水 为溶剂， 反应 0.17h， 生成 Piperidine, 1-heptyl-4-methyl
  参考文献：
  名称：

  筑波链霉菌和链霉菌链亚胺还原酶亚胺还原酶还原胺化范围的光度表征

  摘要：

  两种酶663种组合：在快速光度NADPH分析中确定了由两种有前途的亚胺还原酶催化的还原胺化中的底物范围。可以接受从醛到酮以及从伯胺到仲胺的各种底物，因此可以使用各种仲胺和叔胺产品。

  DOI：

  10.1002/cbic.201700257

文献信息

• [EN] Phosphatase Binding Compounds and Methods of Using Same<br/>[FR] COMPOSÉS DE LIAISON À LA PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV YALE

  公开号：WO2020146470A1

  公开（公告）日：2020-07-16

  The present invention provides bifunctional compounds that efficiently dephosphorylate certain phospho-activated target proteins. Such target proteins can be any protein involved in the pathway of a disease or disorder, such as but not limited to cancer, neurodegeneration, metabolic disease, diabetes, insulin resistance, and so forth.

  本发明提供了能够高效去磷酸化特定磷酸激活靶蛋白的双功能化合物。这些靶蛋白可以是与疾病或紊乱途径有关的任何蛋白质，比如但不限于癌症、神经退行性疾病、代谢性疾病、糖尿病、胰岛素抵抗等。
• Compositions and methods for enhancing proteasome activity
  申请人：President and Fellows of Harvard College

  公开号：US10351568B2

  公开（公告）日：2019-07-16

  Proteinopathies result from the proteasome not acting efficiently enough to eliminate harmful proteins and prevent the formation of the pathogenic aggregates. As described herein, inhibition of proteasome-associated deubiquitinase Usp14 results in increased proteasome efficiency. The present invention therefore provides novel compositions and methods for inhibition of Usp14, enhancement of proteasome activity and treatment of proteinopathies.

  蛋白病症是由于蛋白酶体不能有效地消除有害蛋白质并防止致病聚集体的形成。如本文所述，抑制蛋白酶体相关的去泛素化酶 Usp14 可提高蛋白酶体的效率。因此，本发明提供了抑制 Usp14、增强蛋白酶体活性和治疗蛋白质病的新型组合物和方法。
• 5-HT4 RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0604494B1

  公开（公告）日：1999-07-28
• EIS INHIBITORS
  申请人：University of Kentucky Research Foundation

  公开号：US20170174639A1

  公开（公告）日：2017-06-22

  Provided herein are novel small-molecules that have use in the inhibition of Eis, which mediates kanamycin resistance in Mycobacterium tuberculosis . The presently-disclosed subject matter further includes a pharmaceutical composition including a small molecule inhibitor, as described herein, and a suitable pharmaceutical carrier. Methods of treating tuberculosis comprising administering to an individual an effective amount of the disclosed small molecule inhibitors to mediate kanamycin A resistance and treat tuberculosis are also provided.